@FiercePharma: Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets. Release | Follow @FiercePharma
@EricPFierce: Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M. More | Follow @EricPFierce
@CarlyHFierce: Cue more drama in Teva's boardroom as its CEO announcement nears. Yesterday's story | Follow @CarlyHFierce
> Members of Britain's Parliament continue to expresss displeasure over how much the goverment has spent on Roche's Tamiflu, given the questions over its effectiveness. Story
> Johnson & Johnson's ($JNJ) newest plant in China will be its first in the western part of the country. Report
> Teva Pharmaceutical Industries ($TEVA) has launched an authorized generic of Pfizer's ($PFE) incontinence drug Detrol. Release
> Boehringer Ingelheim is buying more real estate in Columbus, OH. Report
> Spanish blood products group Grifols has gotten a $1.5 billion bridge loan to assist with its buyout of the blood transfusion testing unit of Novartis ($NVS). Item
@FierceMedDev: The CFO of troubled Mela Sciences resigned on Dec. 31. CEO Rose Crane is filling in. Release | Follow @FierceMedDev
@MichaelGFierce: Gene therapy technique from Washington University in St. Louis targets tumor blood vessels. Article | Follow @MichaelGFierce
@GalenMoore: Drug companies accused of holding back complete information on clinical trials. Story | Follow @GalenMoore
> Nipro is recalling glucose meters over a display mixup. More
> Quidel entices investors with FDA thumbs-up for strep test. News
> Boston Scientific looks to follow up on a big 2013. Report
Biotech News
@FierceBiotech: Marina Biotech, Mirna Therapeutics amend license deal to develop microRNA-based therapeutics. Release | Follow @FierceBiotech
@JohnCFierce: Top FierceBiotech story yesterday: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. More | Follow @JohnCFierce
@DamianFierce: The long, strange trip that was Wright Medical's 2013. Report | Follow @DamianFierce
@EmilyMFierce: Cancer Research UK to repurpose an AstraZeneca asthma drug for kidney cancer. Story from FierceBiotech Research | Follow @EmilyMFierce
> Ambitious HDL program joins a growing list of high-profile clinical failures. Story
> A step ahead of controversial transparency rules, Sanofi commits to open access. Report
> NeXeption raises $21.5M to launch dermatology startup Alexar. Article
And Finally... A new report on opioid pain drugs faults many developing countries for restricting their use to stop abuse, saying it is causing a global pain pandemic. Story